According to the American Cancer Society, this treatment involves extracting a patient’s T cells (a type of white blood cell), genetically reprogramming them in a lab to recognise and attack cancer cells, and reinfusing them into the patient.
The study noted strong in vivo persistence of CAR30-positive cells, which were still detectable in 60 per cent of evaluable patients a year after infusion.
Of those in complete remission, 60 per cent remained relapse-free after a median follow-up of 34 months, highlighting the long-term efficacy of the therapy.
The story "This cancer therapy stunned researchers. Here's what the trial revealed" has 710 words across 44 sentences, which will take approximately 3 - 6 minutes for the average person to read.
Which news outlet covered this story?
The story "This cancer therapy stunned researchers. Here's what the trial revealed" was covered 15 hours ago by Business Standard, a news publisher based in India.
How trustworthy is 'Business Standard' news outlet?
Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news.
The outlet is headquartered in India and publishes an average of 254 news stories per day.
It's most recent story was published 3 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
